Key result
The combination of serum cystatin C ≥1.08 mg/L and dyslipidemia was associated with an increased risk of hypertension compared to cystatin C <0.82 mg/L (OR 2.038; 95% CI 1.937-2.143).
Why the study?
Serum cystatin C and dyslipidemia are independently associated with hypertension, but the combined effect of the two factors remains unknown.
Is the combination of elevated serum cystatin C and dyslipidemia associated with an increased risk of hypertension in health check-up subjects?
Cross-Sectional (n=203,233)
Is the combination of elevated serum cystatin C and dyslipidemia associated with an increased risk of hypertension in health check-up subjects?
Odds Ratio: 2.038 (95% CI 1.937–2.143)
The combination of elevated serum cystatin C and dyslipidemia is associated with a significantly increased risk of hypertension in a concentration-dependent manner.
Association does not imply causation and should not alter practice; hypothesis-generating for longitudinal validation in check-up cohorts.
OBJECTIVE: Some studies have reported that both serum cystatin C (Cys C) and dyslipidemia are independently associated with hypertension. However, the combined effect of the two factors is still unknown. The present study was aimed at investigating the effect of Cys C combined with dyslipidemia on hypertension in a large health check-up population in China. METHODS: A total of 203 233 health check-up subjects from January 2011 to July 2016 were recruited into this cross-sectional study. A multivariate logistic regression model was used to evaluate the combined effect of Cys C and dyslipidemia on hypertension.RESULTS: In univariate analysis, Cys C, high-density lipoprotein cholesterol, low-density lipoprotein, total cholesterol, and triglycerides were independently correlated with hypertension (p < 0.001). A concentration-dependent combined effect of serum Cys C and dyslipidemia on hypertension was observed in multivariate regression analysis. When compared with Cys C of <0.82 mg/L, the risk of hypertension in Cys C of <0.82 mg/L with dyslipidemia, Cys C of 0.82–0.94 mg/L with dyslipidemia, Cys C of 0.94–1.08 mg/L with dyslipidemia, and Cys C of ≥1.08 mg/L with dyslipidemia was increased 1.946 (95% confidence interval [CI]: 1.827–2.074), 1.973 (95% CI: 1.864–2.088), 2.047 (95% CI: 1.941–2.158), and 2.038 (95% CI: 1.937–2.143) folds, respectively, after adjustment.CONCLUSION: There was an association between hypertension and the combined effect of Cys C with dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2018) conducted a cross-sectional in hypertension (n=203,233). Serum cystatin C ≥1.08 mg/L combined with dyslipidemia vs. Cystatin C <0.82 mg/L was evaluated on hypertension (OR 2.038, 95% CI 1.937-2.143). The combination of serum cystatin C ≥1.08 mg/L and dyslipidemia was associated with an increased risk of hypertension compared to cystatin C <0.82 mg/L (OR 2.038; 95% CI 1.937-2.143).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: